Skip to main content
MedPathMedPath Home
Clinical Trials/PACTR202308652843585
PACTR202308652843585
Not yet recruiting
未知

Clinical Diagnostic Performance Evaluation of an Anti-Measles IgM Lateral Flow Immunochromatographic Assay for Outbreak Detection and Surveillance in Senegal

Institut Pasteur de Dakar0 sites850 target enrollmentAugust 4, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMeaslesPaediatrics

Overview

Phase
未知
Intervention
Not specified
Conditions
Measles
Sponsor
Institut Pasteur de Dakar
Enrollment
850
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 4, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients (all ages) presenting to participating health centres:
  • •\- For whom confirmatory diagnostic testing is currently indicated as per the national surveillance protocol
  • •\- With clinical signs and symptoms consistent with the WHO suspected measles case definition including: History of fever, or observed fever (\>37\.5C) at presentation and a (non\-vesicular) maculopapular rash; or clinically suspected measles
  • •\- \= 28 days after the onset of a rash
  • •\- Who if \<18 years of age, have written, informed consent from their legal guardian (and verbally assent if more than 7 years old)
  • •\- Who if more than 18 years, give written, informed consent

Exclusion Criteria

  • •\- Withdrawal of consent or assent as described above, at any time.
  • •\- Unsuccessful venous blood sampling after a maximum of 3 attempts, or a serum sample is no longer available for any reason.
  • •\- Clinical signs or symptoms requiring immediate referral/transfer of the patient to another site or centre, and/or for whom participation would involve a delay of urgent clinical interventions or investigations
  • •\- Clinical signs or symptoms that may be exacerbated by blood draw or upper respiratory sampling (e.g. stridor or severe respiratory distress)
  • •\- Prior recruitment to the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
A study on the assessment of diagnostic and therapeutic efficacy using contrast-enhanced FDG-PET/CT for cardiac sarcoidosisCardiac sarcoidosis
JPRN-UMIN000046704Ehime university50
Completed
Not Applicable
Investigation and validation of the diagnostic performance of new biomarker candidates for (I) the early detection of an infectious origin of neutropenic fever and for the prediction of (II) an infection of patients after apoplectic stroke and the progression of (III) a nosocomial infection or (IV) a community acquired pneunomia to a severe sepsis/ septic shockA41.9Sepsis, unspecified
DRKS00004159Institut für Klinische Chemie und Laboratoriumsdiagnostik / Integriertes Forschungs- und Behandlungszentrum Sepsis und Sepsisfolgen1,018
Not yet recruiting
Not Applicable
A clinical study to compare effectiveness of screening of retinal conditions of an eye by a software in detecting retinal diseases (diseases related to back of your eye) by processing undilated (without dilating the eyes) retinal fundus (interior surface of the eye) photographs.
CTRI/2019/04/018420Carl Zeiss India Pvt Ltd
Not yet recruiting
Not Applicable
Evaluation of indigenous K8 spider device for sample collection and concentration for diagnosing Childhood TB
CTRI/2023/11/059979Indian Council of Medical Research
Active, not recruiting
Phase 1
A clinical study in men with prostate cancer undergoing surgery to assess the accuracy of 99mTc-MIP-1404 imaging as compared to pathology resultsProstate Cancer within prostate gland and metastatic prostate cancer in regional lymph nodesMedDRA version: 14.1Level: LLTClassification code 10007113Term: Cancer of prostateSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2012-001864-30-BEMolecular Insight Pharmaceuticals, Inc100